Head to Head Contrast: Organon & Co. and SeaStar Medical

Analysts see more upside potential in SeaStar Medical's stock compared to Organon & Co.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

SeaStar Medical (NASDAQ:ICU) and Organon & Co. (NYSE:OGN) are both small-cap medical companies, but analysts believe SeaStar Medical has more favorable growth prospects based on its higher potential upside. The article compares the two companies across various financial metrics, institutional ownership, and analyst recommendations.

Why it matters

This analysis provides investors with a side-by-side comparison of two small-cap medical companies, highlighting their relative strengths and weaknesses. Understanding the differences between SeaStar Medical and Organon & Co. can help investors make more informed decisions about which stock may be the better investment opportunity.

The details

The key differences between SeaStar Medical and Organon & Co. include revenue, earnings, valuation, profitability, and institutional ownership. Organon & Co. has higher revenue and earnings, but SeaStar Medical is trading at a lower price-to-earnings ratio, indicating it may be more affordable. Additionally, SeaStar Medical has a much lower level of institutional ownership compared to Organon & Co., which could signal more upside potential if it is able to attract more institutional investors.

  • The analysis was published on March 4, 2026.

The players

SeaStar Medical Holding Corporation

A medical device company that develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States.

Organon & Co.

A science-based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the relative strengths and weaknesses of two small-cap medical companies, SeaStar Medical and Organon & Co. While Organon & Co. has higher revenue and earnings, analysts see more upside potential in SeaStar Medical's stock based on its lower valuation and higher projected price target. Investors looking to gain exposure to the medical sector may want to further research these two companies to determine which one aligns better with their investment goals and risk tolerance.